Cargando…

Vitrectomy for macular edema due to retinal vein occlusion

Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheath...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Kazuyuki, Ogino, Nobuchika, Fukami, Marie, Furukawa, Mariko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580136/
https://www.ncbi.nlm.nih.gov/pubmed/31354231
http://dx.doi.org/10.2147/OPTH.S203212
_version_ 1783427977994829824
author Kumagai, Kazuyuki
Ogino, Nobuchika
Fukami, Marie
Furukawa, Mariko
author_facet Kumagai, Kazuyuki
Ogino, Nobuchika
Fukami, Marie
Furukawa, Mariko
author_sort Kumagai, Kazuyuki
collection PubMed
description Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheathotomy, radial optic neurotomy, and intravitreal triamcinolone acetonide injection at the end of the surgery. The main outcome was the best-corrected visual acuity (BCVA). Results: Eight hundred and fifty-four eyes of 854 patients were studied. The eyes consisted of 602 with branch RVO (BRVO), 74 with hemi-central RVO (hemi-CRVO), 87 with nonischemic central retinal vein occlusion (CRVO), and 91 with ischemic CRVO. The mean follow-up period was 68.6 months with a range of 12 to 262 months. The mean BCVA was significantly improved at the final visit (P<0.0001 to 0.0016). The final BCVA improved in 74.4% of the BRVO eyes, in 58.1% of the hemi-CRVO eyes, in 57.4% of the nonischemic CRVO eyes, and in 51.6% of the ischemic CRVO eyes. Multiple regression analysis showed there was no significant relationship between the intraoperative combined procedures and the final BCVA. Conclusions: The results indicate that the type of RVO is significantly associated with the final BCVA, and vitrectomy is a treatment option to improve and maintain BCVA for a long term.
format Online
Article
Text
id pubmed-6580136
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65801362019-07-26 Vitrectomy for macular edema due to retinal vein occlusion Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko Clin Ophthalmol Original Research Purpose: To determine the long-term outcomes of vitrectomy for the macular edema associated with a retinal vein occlusion (RVO). Methods: This was a retrospective, consecutive, interventional case series. The intraoperative procedures included internal limiting membrane peeling, arteriovenous sheathotomy, radial optic neurotomy, and intravitreal triamcinolone acetonide injection at the end of the surgery. The main outcome was the best-corrected visual acuity (BCVA). Results: Eight hundred and fifty-four eyes of 854 patients were studied. The eyes consisted of 602 with branch RVO (BRVO), 74 with hemi-central RVO (hemi-CRVO), 87 with nonischemic central retinal vein occlusion (CRVO), and 91 with ischemic CRVO. The mean follow-up period was 68.6 months with a range of 12 to 262 months. The mean BCVA was significantly improved at the final visit (P<0.0001 to 0.0016). The final BCVA improved in 74.4% of the BRVO eyes, in 58.1% of the hemi-CRVO eyes, in 57.4% of the nonischemic CRVO eyes, and in 51.6% of the ischemic CRVO eyes. Multiple regression analysis showed there was no significant relationship between the intraoperative combined procedures and the final BCVA. Conclusions: The results indicate that the type of RVO is significantly associated with the final BCVA, and vitrectomy is a treatment option to improve and maintain BCVA for a long term. Dove 2019-06-13 /pmc/articles/PMC6580136/ /pubmed/31354231 http://dx.doi.org/10.2147/OPTH.S203212 Text en © 2019 Kumagai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kumagai, Kazuyuki
Ogino, Nobuchika
Fukami, Marie
Furukawa, Mariko
Vitrectomy for macular edema due to retinal vein occlusion
title Vitrectomy for macular edema due to retinal vein occlusion
title_full Vitrectomy for macular edema due to retinal vein occlusion
title_fullStr Vitrectomy for macular edema due to retinal vein occlusion
title_full_unstemmed Vitrectomy for macular edema due to retinal vein occlusion
title_short Vitrectomy for macular edema due to retinal vein occlusion
title_sort vitrectomy for macular edema due to retinal vein occlusion
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580136/
https://www.ncbi.nlm.nih.gov/pubmed/31354231
http://dx.doi.org/10.2147/OPTH.S203212
work_keys_str_mv AT kumagaikazuyuki vitrectomyformacularedemaduetoretinalveinocclusion
AT oginonobuchika vitrectomyformacularedemaduetoretinalveinocclusion
AT fukamimarie vitrectomyformacularedemaduetoretinalveinocclusion
AT furukawamariko vitrectomyformacularedemaduetoretinalveinocclusion